SCHEMBL2393859

SCHEMBL2393859

NC(=O)C(O)c1ccc(F)cc1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.42
MAPT P10636 4/20 0.40
MAP2 P11137 1/20 0.40
GRM2 Q14416 1/20 0.40
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40
EPHX1 P07099 1/20 0.38
HTT P42858 1/20 0.38
PTGS1 P23219 3/20 0.37
MEN1 O00255 2/20 0.37
PTGS2 P35354 2/20 0.37
KMT2A Q03164 2/20 0.37
KCNN4 O15554 2/20 0.37
KDM4E B2RXH2 1/20 0.37
FABP2 P12104 1/20 0.37
TSHR P16473 1/20 0.37
AKR1C4 P17516 1/20 0.37
ADRA2B P18089 1/20 0.37
CHRM3 P20309 1/20 0.37
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395162 0.89 PARP1 (0.41) CES2CES1EPHX1KCNN4
SCHEMBL2393640 0.88 MAPT (0.40) BCAT2MAPTMAP2GRM2CES2
SCHEMBL21052231 0.87 PTGS1 (0.42) BCAT2MAPTCES2CES1HTT
SCHEMBL21052205 0.87 PTGS1 (0.42) BCAT2MAPTCES2CES1HTT
SCHEMBL21052208 0.87 PTGS1 (0.42) BCAT2MAPTCES2CES1HTT
SCHEMBL2393512 0.82 APP (0.47) CES2CES1CHRM3AKR1C3AKR1C2
SCHEMBL9890802 0.81 SLC6A4 (0.44) BCAT2MAPTGRM2EPHX1PTGS1
SCHEMBL9890689 0.81 CHRM3 (0.42) MAPTHTTPTGS1MEN1PTGS2
SCHEMBL9890808 0.80 PTPN1 (0.43) CES2CES1KCNN4
SCHEMBL2393221 0.80 SLC9A1 (0.42) CES2CES1EPHX1HTTKCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885MAPT 3986/4885MAP2 587/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885MAPT 3986/4885MAP2 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.